Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,900 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 6 December 2021) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

 (PDF, 4MB, 245 pages) 

This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website

 

 

Export 6 results:
Author Title [ Type(Desc)] Year
Filters: Author is Fenici, P.  [Clear All Filters]
Journal Article
J. P. H. Wilding, Godec, T., Khunti, K., Pocock, S., Fox, R., Smeeth, L., Clauson, P., Fenici, P., Hammar, N., and Medina, J., Changes in HbA1c and weight after initiation of second-line therapy in patients with type 2 diabetes in clinical practice., Diabetologia., vol. 60, p. S301, 2017.
J. Wilding, Godec, T., Khunti, K., Pocock, S., Fox, R., Smeeth, L., Clauson, P., Fenici, P., Hammar, N., and Medina, J., Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink, BMC Med, vol. 16, p. 116, 2018.
P. H. Wilding J, Rigney, U., Blak, B. T., Nolan, S. T., Fenici, P., and Medina, J., Glycaemic, weight, and blood pressure changes associated with early versus later treatment intensification with dapagliflozin in United Kingdom primary care patients with type 2 diabetes mellitus, Diabetes Res Clin Pract, p. 107791, 2019.
H. J. L. Heerspink, Karasik, A., Thuresson, M., Melzer-Cohen, C., Chodick, G., Khunti, K., Wilding, J. P. H., Rodriguez, L. A. Garcia, Cea-Soriano, L., Kohsaka, S., Nicolucci, A., Lucisano, G., Lin, F. J., Wang, C. Y., Wittbrodt, E., Fenici, P., and Kosiborod, M., Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study, Lancet Diabetes Endocrinol, vol. 8, pp. 27-35, 2020.
M. Kosiborod, Cavender, M. A., Fu, A. Z., Wilding, J. P., Khunti, K., Holl, R. W., Norhammar, A., Birkeland, K. I., Jorgensen, M. E., Thuresson, M., Arya, N., Bodegard, J., Hammar, N., and Fenici, P., Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotranspo, Circulation, vol. 136, pp. 249-259, 2017.
M. A. Cavender, Norhammar, A., Birkeland, K. I., Jorgensen, M. E., Wilding, J. P., Khunti, K., Fu, A. Z., Bodegard, J., Blak, B. T., Wittbrodt, E., Thuresson, M., Fenici, P., Hammar, N., and Kosiborod, M., SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL, J Am Coll Cardiol, vol. 71, pp. 2497-2506, 2018.
[Page last reviewed 6 December 2021]